Mitochondria-Targeted Antioxidants and Uncouplers of Oxidative Phosphorylation in Treatment of the Systemic Inflammatory Response Syndrome (SIRS).
J Cell Physiol
; 232(5): 904-912, 2017 05.
Article
en En
| MEDLINE
| ID: mdl-27684052
ABSTRACT
Systemic inflammatory response syndrome (SIRS) development is accompanied by mitochondrial dysfunction and excessive ROS production. Mitochondrial dysfunctions also occur in many SIRS-related diseases and may be critical for their pathogenesis; therefore, a use of mitochondria-targeted drugs is a promising trend in SIRS research and therapy. Here, we review recent studies concerning the application of the mitochondria-targeted antioxidants and uncouplers of oxidative phosphorylation in animal models of SIRS and related diseases. We propose that a new class of uncouplers of oxidative phosphorylation, lipophilic cations could be a base for a new generation of drugs for SIRS treatment. J. Cell. Physiol. 232 904-912, 2017. © 2016 Wiley Periodicals, Inc.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fosforilación Oxidativa
/
Síndrome de Respuesta Inflamatoria Sistémica
/
Mitocondrias
/
Antioxidantes
Límite:
Animals
/
Humans
Idioma:
En
Año:
2017
Tipo del documento:
Article